Drug Approval | January 24, 2025
Shilpa Pharma Lifesciences received CEP from EDQM for API, Teriflunomide
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
This is used to treat central diabetes insipidus and bedwetting
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
